Signaling pathways
-
BA9022 Lck-IN-1Summary: A potent lymphocyte protein tyrosine kinase inhibitor. -
BA9023 LanraplenibSummary: Lanraplenib (GS-9876) is a highly selective oral inhibitor (=9.5 nM) for the study of inflammatory diseases. - BA9024 SovleplenibSummary: Sovalleplenib (HMPL-523) is a potent, orally available selective inhibitor.
- BA9025 CevidoplenibSummary: Cevidoplenib (SKI-O-703) is an orally active spleen tyrosine kinase inhibitor with potential anti-inflammatory and immunomodulatory effects.
- BA9026 R112Summary: R112 is a rapid and reversible kinase inhibitor of spleen tyrosine kinase.
- BA9027 Syk-IN-1Summary: Syk-IN-1 is a potent inhibitor.
- BA9028 Syk-IN-4Summary: Syk-IN-4 is a potent, selective inhibitor with oral activity.
- BA9029 ER-27319Summary: ER-27319 is an acridone derivative.
- BA9030 UNC2541Summary: UNC2541 is a potent Mer tyrosine kinase-specific inhibitor.
- BA9031 UNC569Summary: UNC569 is a potent, reversible, ATP-competitive and orally active kinase inhibitor.